PrEP, a new HIV prevention method where HIV negative individuals take antiretrovirals to prevent infection, was approved in Belgium in June 2017. Concerns have been raised by communities, HIV prevention organisations, sexual health organisations, users, healthcare providers and public health institutions regarding adequate reach, delivery and use. Important questions on whether how the demonstrated clinical efficacy of PrEP will translate into population-level effectiveness are still unanswered. The overall objective of this project is to learn how PrEP rollout can be optimized to result in maximum impact on HIV and sexual health.
|Effectieve start/einddatum||1/01/19 → 31/12/22|
- Fonds voor Wetenschappelijk Onderzoek: 1.888.025,00 €